Avadel制药 AVDL 深 沪
等待开盘 04-02 09:30:00 美东时间
21.64
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 21.64
- 总市值 21.24亿
- 52周最高 23.57
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 6.38
- 委 比 0.00%
- 总股本 9815.15万
- 历史最高 23.57
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.03
- 每 手 1
- 风险率 5.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics Inc. has appointed Susan Rodriguez as Chief Commercial and Strategy Officer. In this role, she will lead the company's commercial strategy and infrastructure development as it prepares to submit an NDA for ALXN1840, its investigational therapy for Wilson disease. With over 30 years of experience in biopharmaceutical leadership, Rodriguez brings a proven track record of successfully launching rare disease therapies and scaling...
03-02 13:00
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing
The Irish High Court has approved Avadel Pharmaceuticals' scheme of arrangement with its shareholders, allowing Alkermes to acquire all of Avadel's issued and to-be-issued ordinary shares. The court order must be delivered to the Registrar of Companies by February 11, 2026, for the scheme to take effect on February 12. Trading of Avadel shares on Nasdaq is expected to halt on February 11.
02-10 21:05
Avadel Pharmaceuticals Shareholders Approve Proposed Takeover By Alkermes
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a public limited company incorporated in Ireland ("Avadel" or the "Company") announces today that, in relation to the previously announced offer for the Company by Alkermes plc,
01-13 05:08
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
Avadel Pharmaceuticals shareholders have approved the proposed transaction with Alkermes plc, including the scheme of arrangement and amendments to the company’s articles of association, at a special meeting held earlier today. Shareholders also approved the proposed compensatory arrangements for the transaction. Avadel is a biopharmaceutical company focused on transforming medicines to improve patient lives, with LUMRYZ™ as its commercial produc...
01-12 21:05
Catalyst Watch: Big bank earnings, major healthcare + retail conferences, Fedspeak flurry, CPI
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 1...
01-10 04:00
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
那些关于药品定价政策及可能侵蚀利润的关税措施的最坏担忧均未成真，行业焦虑情绪得到明显缓解。 智通财经APP获悉，下周，制药商们将赴旧金山出席摩根大通医疗健康年...
01-10 00:49
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
下周，制药商们将赴旧金山出席摩根大通医疗健康年会，心态较2025年显著放松。回溯一年前，他们还对美国总统唐纳德·特朗普的政策走向感到困惑迷惘;如今，此前笼罩的诸...
01-09 21:50
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-02 01:35
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
Avadel Pharmaceuticals completed patient enrollment in the Phase 3 REVITALYZ trial evaluating LUMRYZ as a potential treatment for idiopathic hypersomnia (IH). The trial aims to assess LUMRYZ's efficacy and safety as a once-at-bedtime treatment for IH, targeting excessive daytime sleepiness and sleep inertia. LUMRYZ, an extended-release sodium oxybate, has shown benefits for narcolepsy patients and holds potential for IH if approved. Data expected...
2025-12-18 12:00
Avadel Pharmaceuticals Acquisition Moves Forward with HSR Expiry
Avadel Pharmaceuticals ( ($AVDL) ) has issued an update. On December 8, 2025, t...
2025-12-10 05:52
